SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 12/11/2017 7:41:37 PM - Followers: 732 - Board type: Free - Posts Today: 333

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
PostSubject
#207221  Sticky Note Re B-OM Ph2 topline: A Lead-Off Stand-Up Double slcimmuno 12/11/17 08:36:46 AM
#205289  Sticky Note Due diligence: Innovation Pharmaceuticals Inc. (IPIX) BooDog 11/30/17 06:20:08 AM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#206759   Not directionless. Base building after a run up. Citrati 12/07/17 03:19:17 PM
#206758   But my experience has been that Leo F1ash 12/07/17 03:16:47 PM
#206757   AA is possible, but only with exceptional results. PlentyParanoid 12/07/17 03:14:45 PM
#206756   I guess I was not clear enough. I PlentyParanoid 12/07/17 03:02:22 PM
#206755   Without seeing the trial protocol it is impossible PlentyParanoid 12/07/17 02:58:54 PM
#206754   Couple small gaps to fill before news. scottsmith 12/07/17 02:58:44 PM
#206753   Directionless afternoon. 1.05 to 1.08 who will prevail? Rdunn88 12/07/17 02:57:32 PM
#206750   A lot has changed since December 2015. The sox040713 12/07/17 02:44:33 PM
#206749   Let it rip!!!!!!!!! Matagordaville 12/07/17 02:43:20 PM
#206748   That is why I say, short septmike09 12/07/17 02:41:57 PM
#206747   Nonsense!!! It's Aspire that's made shareholder wealth possible!!! DaysOnTheBeach 12/07/17 02:39:48 PM
#206746   Someone is losing out on some big cash. septmike09 12/07/17 02:39:13 PM
#206745   Could be after hours today for data. Look BooDog 12/07/17 02:28:27 PM
#206744   We know that Leo knows Joe Biden whose govorchin 12/07/17 02:28:26 PM
#206743   Wow - the accelerated approval discussion started - Amatuer17 12/07/17 02:27:25 PM
#206742   I think accelerated approval is more for cancer sox040713 12/07/17 02:20:07 PM
#206741   The placebo rate in Otezla’s Esteem 1&2 runs Yooper61 12/07/17 02:19:56 PM
#206740   It gon rain $$$$$IPIX Cgerd 12/07/17 02:14:01 PM
#206739   ok, so its next week.... 123tom 12/07/17 02:13:23 PM
#206738   Where did the party go? Trading comes to Rdunn88 12/07/17 02:12:47 PM
#206737   This is a good observation. Most people scottsmith 12/07/17 02:08:45 PM
#206736   Aspire continues to erode shareholder wealth. That MXAMDUD 12/07/17 02:07:36 PM
#206735   Revisit your chart: look at the move in MXAMDUD 12/07/17 02:05:46 PM
#206734   Small blocks dumped. My guess it's our friend Aspire... Rdunn88 12/07/17 02:05:17 PM
#206733   I don't think it's a brick wall at 1.07 123tom 12/07/17 02:01:28 PM
#206732   I always liked Patrick's analysis. 123tom 12/07/17 01:53:47 PM
#206731   mid day- pausing today... 123tom 12/07/17 01:48:46 PM
#206730   Filled! Pepperchino 12/07/17 01:43:55 PM
#206729   Sure. Actually, highly unlikely offers come without several BioTechMaven 12/07/17 01:42:38 PM
#206728   Yep, but first a partnership, then uplist, that's septmike09 12/07/17 01:41:33 PM
#206727   Looks to be forming a new base at camk 12/07/17 01:41:19 PM
#206726   I expect IPIX will be gobbled up by BioTechMaven 12/07/17 01:37:08 PM
#206725   Partially filled some 1.07s and waiting patiently for Pepperchino 12/07/17 01:24:19 PM
#206724   I think we’re talking extragalactic potential. :-D TheDane 12/07/17 01:15:30 PM
#206723   Your imaginary brick wall is getting higher and sox040713 12/07/17 01:11:17 PM
#206722   No argument here. I don't do charts so Darwinian 12/07/17 01:06:16 PM
#206721   BioHedge, it’s always good to see you posting sox040713 12/07/17 01:02:16 PM
#206720   we know the DSMB did not conclude the baytdr 12/07/17 12:55:23 PM
#206719   HOLD GREEN!!!! Data any NANOSECOND. scottsmith 12/07/17 12:53:50 PM
#206718   Bio you can't be serious. 5-10 more years? JTORENCE 12/07/17 12:46:33 PM
#206717   as an MD as an MD....sigh To infinity and beyond! 12/07/17 12:43:46 PM
#206716   Why do you pick this exact time to alwaysdreaming 12/07/17 12:36:21 PM
#206715   As an MD, you're likely aware that psoriasis KarinCA 12/07/17 12:35:44 PM
#206714   Fair point on the P comparison. That said, BioHedge 12/07/17 12:35:39 PM
#206713   BIOTECH - On K, is this possibilities? Nice top123 12/07/17 12:35:18 PM
#206712   Eventually we should get well past the moon. G Bert 12/07/17 12:32:49 PM
#206711   Let me read the tee leaves in what tryz 12/07/17 12:27:59 PM
#206710   Here is a previous post with targets. Citrati 12/07/17 12:24:31 PM
#206709   So invest in any company with bullish PR’s? IPIX I scottsmith 12/07/17 12:21:59 PM
#206708   Oral mucositis (OM) doesn't wax and wane like KarinCA 12/07/17 12:20:26 PM
PostSubject